INCY: SEC Form 10-Q filed by Incyte Corp.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for INCY
Across the 27 sessions after earlier INCY headlines, the stock closed higher 10 times and lower 17 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INCY | SPY |
|---|---|---|---|
| Oct 29, 2026 | Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates | -0.1% | -0.4% |
| Oct 26, 2026 | Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 | -2.1% | +0.7% |
| Oct 20, 2026 | Morgan Stanley resumed coverage on Incyte with a new price target | +3.0% | +0.3% |
| Oct 19, 2026 | Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 | +0.2% | +0.4% |
| Oct 8, 2026 | Incyte to Report Third Quarter Financial Results | -0.6% | -0.4% |
| Oct 6, 2026 | Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil | -1.2% | +0.5% |
Quantisnow market dataNASDAQ
INCY
Incyte Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
Get push alerts for INCY
Full INCY profile on Quantisnow Follow INCY and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time